(atdn) new trial for cmv retinitis

AIDS Treatment Data Network (ATDN) New Trial for CMV Retinitis
November 1, 1995

Treatment Review No. 20; November 1995 CMV retinitis is a disease caused by a herpesvirus with which most people have been infected sometime during their lifetime. CMV retinitis can lead to blindness. Only two treatments are currently approved for this infection. A new study of CMV retinitis treatments is being conducted by the AIDS Clinical Trials Group (ACTG). This trial will study the antibody MSL 109 given in combination with either foscarnet or ganciclovir, the two drugs currently approved for the treatment of CMV retinitis. MSL 109 has fewer side effects than either ganciclovir or foscarnet and was tolerated well by participants in earlier studies. MSL 109 is a human anti-CMV antibody that specifically targets CMV infection in the body. It is believed that combining one of the standard treatments for CMV retinitis, ganciclovir or foscarnet, with the anti-CMV antibody will be a more effective treatment. Upon entry into the trial, all participants will be administered either ganciclovir or foscarnet through an IV tube. Participants will then be given one dose of MSL 109 or a placebo also administered through an IV tube. A second dose of MSL 109 or a placebo will be administered after two weeks. For a full description of this study or a referral to call The Network at (800) 734-7104.

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 HIV messages should include MSM Stock-outs must be top of agenda TEXAS: Free HIV Testing CALIFORNIA: Entertainment AIDS Alliance (EAA) Presents 11th Annual Wine and Wisdom Fundraiser NORTH CAROLINA: ALFA Offers Free Community Health Educator Training in Hickory CALIFORNIA: Over Half of People Living with AIDS in San Francisco Are Aged 50 or Older THAILAND; UNITED STATES: HIV Drug Can Also Protect Injection Drug Users INDONESIA: Growing HIV/AIDS Awareness in Indonesia's Papua Region UNITED STATES: Many Young Americans Unaware They're Infected with HIV Board to Vote on Condoms in Boston Schools New International Report on HIV Prevention Urges Localized Consideration of Antiretroviral Strategies New Hampshire nears approval of medical marijuana law New Analysis of World's Premier AIDS Conference Finds Poor Coverage of Populations Most-at-Risk for HIV UNITED STATES: New Compound Excels at Killing Persistent and Drug-Resistant Tuberculosis INDIA: WHO Issues Guide For New TB Drug Civil confinement trial for NY sex offender begins UNAIDS welcomes new findings that provide an additional tool for HIV prevention for people who inject drugs AHF Launches First 1-minute “INSTI” HIV Testing Program in New York City New PrEP Trial Results Among Injecting Drug Users Underscore That PrEP Works When Taken Consistently UNITED KINGDOM: Gonorrhea Becomes More Resistant to Last-Line Antibiotics, but New Guidelines May Stop Its Spread
Copyright © 1995 -AIDS Treatment Data Network, Publisher. All rights reserved to AIDS Treatment Data Network. Reproduction of this article (other than one copy for personal reference) must be cleared through the AIDS Treatment Data Network. Email AIDS Treatment Data Network Information in this article was accurate in November 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.